Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study | Zendy

Fabienne Schochter | Zendy; Brigitte Rack | Zendy; Marie Tzschaschel | Zendy; Arkadius Polasik | Zendy; Ulrich Andergassen | Zendy; Elisabeth Trapp | Zendy; Marianna AlunniFabbroni | Zendy; Andreas Schneeweiß | Zendy; Volkmar Müller | Zendy; Klaus Pantel | Zendy; Jörg Gade | Zendy; Ralf Lorenz | Zendy; Mahdi Rezai | Zendy; Hans Tesch | Zendy; Ulrike Soeling | Zendy; Tanja Fehm | Zendy; Sven Mahner | Zendy; Christian Schindlbeck | Zendy; W. Lichtenegger | Zendy; Matthias W. Beckmann | Zendy; Peter A. Fasching | Zendy; Wolfgang Janni | Zendy; Thomas W. P. Friedl | Zendy

Open Access

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Author(s) -

Fabienne Schochter,

Brigitte Rack,

Marie Tzschaschel,

Arkadius Polasik,

Ulrich Andergassen,

Elisabeth Trapp,

Marianna AlunniFabbroni,

Andreas Schneeweiß,

Volkmar Müller,

Klaus Pantel,

Jörg Gade,

Ralf Lorenz,

Mahdi Rezai,

Hans Tesch,

Ulrike Soeling,

Tanja Fehm,

Sven Mahner,

Christian Schindlbeck,

W. Lichtenegger,

Matthias W. Beckmann,

Peter A. Fasching,

Wolfgang Janni,

Thomas W. P. Friedl

Publication year - 2018

Publication title -

oncology research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.553

H-Index - 48

eISSN - 2296-5262

pISSN - 2296-5270

DOI - 10.1159/000485566

Subject(s) - exemestane , medicine , tamoxifen , tolerability , breast cancer , oncology , adverse effect , cancer , gynecology

Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research